Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -516K | -559K | -872K | 0 | 0 |
| EBITDA | -516K | -559K | -872K | 206K | 172K |
| Net Income | -700K | -684K | -900K | -34K | -34K |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$0.0001
+0.00% today
1Y Change
+100.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Supurva Healthcare Group, Inc. (SPRV) is a Financial Services stock with listed on OTC. The stock last traded around $0.00 and up 100.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.0%, free cash flow +59.4% with operating margin 0.0% and ROIC 25.7%. Stock Foundry combines SPRV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPRV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPRV Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SPRV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$34.2K
-2.0% YoY
Free Cash Flow
$0.0
Revenue Growth
+0.0%
EPS Growth
+50.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -516K | -559K | -872K | 0 | 0 |
| EBITDA | -516K | -559K | -872K | 206K | 172K |
| Net Income | -700K | -684K | -900K | -34K | -34K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3M | 2M | 2M | 2M | 2M |
| Shareholder Equity | -3M | -2M | -2M | -2M | -2M |
| Total Debt | 1M | 1M | 1M | 2M | 2M |
| Net Debt | 1M | 1M | 1M | 2M | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
0
Capital Expenditures
0
Free Cash Flow
0
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
25.5%
Debt / Equity
-0.35x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.